XML 59 R36.htm IDEA: XBRL DOCUMENT v3.25.2

Segment Information (Tables)

12 Months Ended

Jun. 30, 2025

Segment Reporting [Abstract]

Summary of Financial Data for Development of Pharmaceutical Products Segments

The following table summarizes our financial data for the development of pharmaceutical products segment:

		For the Fiscal Year Ended June 30,
		2025				2024
Revenues		$	—			$	65,297
Operating and other (income) expense
Employee expenses			9,293				13,207
Other segment expenses(1)			2,647				9,946
Professional fees			2,754				4,092
Legal fees			1,723				3,397
Impairment of long-lived assets			—				10,899
Fees paid on behalf of a related party			—				1,118
voruciclib			801				3,413
ME-344			253				4,724
Gain on disposition of a non-financial asset			(500	)			—
Interest and dividend income			(1,026	)			(3,277	)
Total operating and other (income) expense			15,945				47,519
Total segment costs (loss) income and net (loss) income		$	(15,945	)		$	17,778

________

(1) Includes product development costs associated with zandelisib determined to be immaterial for both periods presented, occupancy costs (including rent and utilities), share-based compensation costs, depreciation expense, administrative costs, travel and business taxes.

X

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

Name:	us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_SegmentReportingAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration